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Abstract 1 
Purpose:  Tyrosine administration may counter exercise fatigue in a warm environment, but 2 
the typical dose is inconclusive, with little known about higher doses.  We explored how three 3 
tyrosine doses influenced the circulating ratio of tyrosine: amino acids competing for brain 4 
uptake, and hypothesised a medium and high dose would enhance exercise performance in a 5 
warm environment. 6 
Methods:  Eight recreationally trained, non-heat acclimated males [mean (± SD) age, 23 ± 4 7 
years; stature, 181 ± 7 cm; body mass, 76.1 ± 5.9 kg; peak oxygen uptake (V̇O2peak), 4.1 ± 0.5 8 
L·min-1] performed a V̇O2peak test, two familiarisation trials, then four experimental trials in 9 
a randomised order separated by 7 d.  Prior to exercise, subjects drank 2 x 300 mL sugar-free 10 
drinks delivering zero (PLA), 150 (LOW), 300 (MED) or 400 (HIGH) mg·kg body mass-1 11 
tyrosine in a double-blind fashion.  Subjects performed 60 min constant intensity cycling then 12 
a simulated time trial in 30°C and 60% relative humidity. 13 
Results:  Time trial performance (P = 0.579) was not influenced by tyrosine ingestion.  The 14 
plasma ratio of tyrosine: ∑(free-tryptophan, leucine, isoleucine, valine, phenylalanine, 15 
methionine), a key determinant of brain tyrosine influx, increased relative to PLA (P < 0.001).  16 
The increase was similar (P > 0.05) in MED (7.7-fold) and HIGH (8.2-fold), and greater than 17 
LOW (5.3-fold; P < 0.05).  No differences existed between trials in core and skin temperature, 18 
heart rate, RPE or thermal sensation (P > 0.05). 19 
Conclusion:  Exercise performance in a warm environment was not influenced by tyrosine 20 
availability in recreationally trained males.  The results provide novel data informing future 21 
studies, on the tyrosine dose maximising the circulating ratio of tyrosine: amino acids 22 
competing for brain uptake.   23 
Keywords: amino acids, catecholamines, fatigue, warm environment. 24 
 25 
Introduction 26 
The ability to perform prolonged single-limb and whole-body exercise in a hot environment is 27 
impaired compared to the same exercise in cooler conditions (1).  In addition to peripheral 28 
mechanisms such as altered circulatory and fluid balance factors, changes within the central 29 
nervous system (CNS) strongly influence fatigue during prolonged exercise in the heat.  30 
Altered brainwave activity associated with reduced arousal has been reported, thermal 31 
sensation and subjective effort increase during exercise with hyperthermia, voluntary muscle 32 
recruitment declines, which ultimately impair prolonged exercise performance (1).  Reduced 33 
brain catecholamine function is a possible mediator of this central fatigue as dopamine and 34 
noradrenaline are involved in motor initiation and control (2), reward mechanisms and high 35 
motivation and arousal states (3), and heat loss mechanisms during exercise (4).  Reductions 36 
in brain dopamine activity in several brain areas have also been reported at the point of 37 
exhaustion in exercised rats (5).  There may be a similar functional link between CNS 38 
catecholamine impairment and exercise fatigue in humans.   39 
 40 
Brain catecholamine synthesis is largely dependent upon impulse flow through neuronal 41 
populations and adequate precursor availability.  The availability of brain tyrosine, the amino 42 
acid precursor to CNS catecholamine synthesis, is generally adequate under basal conditions, 43 
as the rate-limiting enzyme tyrosine hydroxylase is thought to be near saturation (6).  Dopamine 44 
and noradrenaline neuronal activity in the CNS is strongly upregulated in response to stress (7) 45 
and if the exposure is prolonged, tissue availability of tyrosine can become depleted in neurons 46 
which are firing rapidly, impairing catecholamine synthesis (8).  Under these stressful 47 
conditions, experimentally increasing brain tyrosine content in rats maintains catecholamine 48 
synthesis (8).  Orally administered tyrosine shows promise in reducing decrements in mood 49 
and cognitive function in humans during stress exposure, using doses up to 300 mg·kg body 50 
mass-1 (9, 10) but an optimal tyrosine dose is yet to be established (9).  Several studies have 51 
attempted to influence exercise capacity and performance with 150 mg·kg body mass-1 tyrosine 52 
in healthy subjects (11-15),  with a separate study administering 20 g (16).  Only one of these 53 
studies reported increased exercise capacity in a warm environment (13) with the remainder 54 
unable to confirm an influence of tyrosine on exercise in temperate (11, 12, 16) or warm 55 
environment (14, 15).  This is surprising, considering the demands which prolonged exercise 56 
with hyperthermia places on the CNS (1) and the body of work suggesting a positive influence 57 
of tyrosine on cognitive and psychomotor function during stress exposure.  A key determinant 58 
of brain influx of tyrosine is the circulating concentration ratio to large neutral amino acids 59 
which compete for a common L-carrier system at the blood-brain barrier (17).  Acute 60 
administration of 150 mg·kg body mass-1 increases this ratio several-fold (13, 14, 18), but there 61 
is a lack of data on the effect of higher tyrosine doses in humans.  Considering that tyrosine 62 
administration up to 300 mg·kg body mass-1 is effective in reducing cognitive impairments 63 
during exposure to demanding environmental conditions, it is reasonable to propose that this 64 
might also counter exercise fatigue in warm ambient temperatures. 65 
 66 
The primary aim of this study was to examine the effect of three different tyrosine doses on the 67 
ability to perform prolonged endurance exercise in a warm environment.  We hypothesised that 68 
a tyrosine dose similar to that used in the majority of previous exercise studies (defined as a 69 
low dose for the purpose of this study) (11-15) would not influence, but that a medium or high 70 
dose would enhance cycling performance in in a warm environment, compared to a placebo 71 
containing no tyrosine.  A secondary aim was to describe the effects of several acute tyrosine 72 
doses on the circulating ratio of tyrosine to amino acids competing for brain influx.   73 
 74 
Methods 75 
Subjects and ethics procedures 76 
Nine healthy recreationally trained male volunteers, who were unacclimated to exercise in a 77 
warm environment, were recruited for the study.  All testing took place in the Autumn and 78 
Winter months in Wales within the UK when air temperature is typically 15°C or lower.  All 79 
subjects were permanently resident in the UK for at least one month before commencing the 80 
study.  One volunteer withdrew from the study before completing all testing due to time 81 
constraints outside the study, and the remaining eight completed all testing [mean (± SD) age, 82 
23 ± 4 years; stature, 181 ± 8 cm; body mass, 76.1 ± 5.9 kg; absolute peak oxygen uptake 83 
(V̇O2peak) from ramp incremental test, 4.2 ± 0.5 L·min
-1; relative V̇O2peak, 55.1 ± 7.1 84 
mL·kg·min-1; absolute peak power achieved during ramp test, 327 ± 38 W; relative peak power 85 
from ramp test, 4.3 ± 0.5 W·kg-1; maximal heart rate during ramp test, 185 ± 8 beats·min-1].  86 
Subjects were not all specifically trained endurance cyclists but had a minimum of three years 87 
training history, and participated in sports training at least 3 days per week, for a minimum of 88 
3.5 hours total per week (classified as performance level 2) (19).  Verbal and written 89 
information was given on the protocol and subjects were allowed to ask questions before 90 
providing written informed consent to proceed with the study.  Subjects were free to withdraw 91 
from the study without prior notice, and without any penalty.  The study was approved by the 92 
Research Ethics Committee at Aberystwyth University (reference number 14611). 93 
 94 
Experimental procedures 95 
The experimental procedures are similar to a previous study conducted in our lab (14).  Subjects 96 
completed initial testing to measure V̇O2peak then 48 h later, they performed the first of two 97 
familiarisation trials separated by 7 days, and one week later the first of four experimental 98 
trials, each separated by 7 days.  Randomisation of the experimental trial order was carried out 99 
using an open source software package (PEPI for Windows, Brixton Health).  All experimental 100 
trials started in the morning between 0700 and 0830, and at the same time for each participant 101 
at each subsequent visit.  A 24 h dietary intake record was completed by each subject before 102 
the first familiarisation, to enable diet replication before each experimental trial, but diet was 103 
not analysed. Subjects arrived for each experimental trial after an overnight fast of at least 8 h 104 
except for drinking 500 mL ordinary tap water 2 h before arrival.  Subjects were instructed to 105 
sleep at least 8 h the night before to ensure they were well rested and verbal confirmation of 106 
adherence to these instructions was obtained at each visit.  The consumption of alcohol and 107 
participation in strenuous or unaccustomed physical activity was not permitted for 48 h prior 108 
to each laboratory visit. 109 
 110 
Initial testing 111 
Subject’s height (Holtain Ltd, Crymych, UK) and nude body mass (Seca 899, Hamburg, 112 
Germany) were recorded and they were fitted with a radiotelemetric heart rate monitor (Polar, 113 
FS2C, Kempele, Finland).  Seat height and handle bar position was adjusted on an electrically 114 
braked cycle ergometer (Lode Excalibur Sport 2, Groningen, Netherlands) and replicated for 115 
each subject in subsequent visits.  Exercise commenced for 3 min at 0 W then power output 116 
increased by 1 W every 2 s until volitional exhaustion, operationally defined as an inability to 117 
maintain 60 rpm pedal cadence for 5 s and voluntary withdrawal from exercise.  Subjects were 118 
instructed to remain seated throughout the exercise test and all subjects adhered to these 119 
instructions.  Expired gases were analysed throughout exercise using an online breath-by-120 
breath system (Quark PFT, Cosmed, Rome, Italy) which was calibrated before each test.  Peak 121 
power was recorded as the highest power output achieved and V̇O2peak was identified as the 122 
highest V̇O2 recorded over a consecutive 30 s average during the test. The gas exchange 123 
threshold (GET; defined as non-linear increase in V̇CO2 with a linear increase in V̇O2, 124 
accompanied by an increase in the ventilatory equivalent for oxygen, V̇E/V̇O2, while the 125 
ventilatory equivalent for carbon dioxide, V̇E/V̇CO2, continued to decrease or level off) was 126 
identified for each subject and confirmed by a minimum of two separate, experienced 127 
investigators.  The power output equivalent to 10% ∆ (the V̇O2 at the GET plus 10% of the 128 
difference between the GET and V̇O2peak) was calculated for each subject. 129 
 130 
Familiarisation and experimental trials 131 
The purpose of the familiarisations was to appease any anxiety and to allow the subjects to 132 
become accustomed to the protocol and exercising in the warm environment, and to minimise 133 
any learning effects which might influence performance time.  The familiarisations were 134 
identical to the placebo trial except no blood was drawn.   135 
 136 
Nude body mass was recorded (Seca 899, Hamburg, Germany).  Subjects fully emptied their 137 
bladder so urine volume could be measured and approximately 1 mL urine was retained to 138 
analyse urine osmolality (Osmostat 030, Gonotec, Berlin).  The baseline urine osmolality for 139 
each subject was ≤ 700 mosmol·kg-1 at each laboratory visit, so all subjects were assumed to 140 
be euhydrated (20).  A radiotelemetry band was fitted to the chest for continuous heart rate 141 
measurement (Polar, FS2C, Kempele, Finland) and skin thermistors (Grant Instruments, 142 
Cambridge, England) were attached using breathable adhesive medical tape (Hypafix, Bsn 143 
Medical, Hull, UK), to the left calf, left anterior thigh, upper left chest, and left posterior upper 144 
arm.  Subjects fitted a rectal thermistor (Grant Instruments, Cambridge, England), in private, 145 
10 cm beyond the anal sphincter.  Rectal temperature (used as in indicator of core temperature) 146 
and skin temperature at four sites were continuously logged using an electronic data logger 147 
(Squirrel SQ2020, Grant Instruments, Cambridge, England).  The skin temperature values were 148 
used to calculate mean weighted skin temperature [0.3·(chest temperature + arm temperature) 149 
+ 0.2·(thigh temperature + calf temperature)] after each trial (21).  Subjects were seated quietly 150 
in the laboratory for 15 min then a blood sample (Baseline) was drawn from a superficial 151 
antecubital vein using a 21-g sterile needle (BD Vacutainer Systems, Plymouth, UK), with 152 
minimal stasis, into a heparinised vacutainer (BD Vacutainer Systems, Plymouth, UK).  A 300 153 
mL drink was administered containing ordinary tap water with 20% sugar-free lemon and lime 154 
flavoured cordial (Morrisons, Bradford, UK), and consumed by the subject within 5 minutes.  155 
The quantity of tyrosine powder (Nutricia Ltd., Liverpool, UK) added to the drink differed, 156 
depending upon on the experimental trial undertaken (see Tyrosine administration below)  157 
 158 
Subjects remained seated quietly in a thermoneutral laboratory (18°C, 50% relative humidity, 159 
RH) for 60 min.  A second venous blood sample (Pre-exercise) was drawn and the second 300 160 
mL drink was administered, as described above. Subjects entered the climate chamber (Design 161 
Environmental, Gwent, Wales), which was maintained at 30°C and 60% RH, and started 162 
cycling (Lode Excalibur Sport 2) without a warm up, at a fixed intensity equivalent to 10% Δ 163 
(129 ± 17 W) for 60 min.  This is defined as heavy intensity exercise and was used to induce 164 
hyperthermia prior to the main performance time trial, without eliciting exhaustion (14). 165 
Subjects were instructed to remain seated throughout all exercise periods and adhered to these 166 
instructions in all trials.  Subjects were provided drinks (2 mL·kg body mass-1 tap water and 167 
20% sugar-free, lemon and lime cordial) after every 15 min of exercise elapsed.  A third venous 168 
blood sample was drawn immediately after 60 min cycling (Post 60 min).  The ergometer was 169 
set in linear mode, so the power output and the work accumulated was directly related to pedal 170 
cadence, and subjects were free to choose their preferred cadence.  A maximum of 2 min 171 
elapsed between the end of the 60 min cycling and the start of the time trial and this time was 172 
standardised for each subject at each experimental trial.  The time trial is based on a validated 173 
protocol used previously (18) and requires completion of an individual work target, equivalent 174 
to the total work required to complete 30 min cycling at 60% of the ramp test power output 175 
eliciting V̇O2peak (326 ± 37 kJ in this group).  Subjects were free to self-pace, but were 176 
instructed to complete their work target as quickly as possible.  The accumulated work portion 177 
of the bike console display was visible to the subjects throughout, with values representing 178 
25%, 50%, 75%, and 100% of their individual work target.  No additional feedback or 179 
motivational encouragement was provided throughout the time trial.  Subjects were permitted 180 
to drink ad-lib throughout (ordinary tap water with 20% sugar-free lemon and lime cordial) 181 
and the volume of fluid consumed was recorded.  Heart rate, core temperature and skin 182 
temperature at five sites were recorded every five minutes throughout the 60 min pre-exercise 183 
period, during the 60 min constant load cycling and the time trial.  Additionally, these were 184 
recorded at completion of the time trial.  Subjective thermal sensation (from -10, unbearable 185 
cold, to +10, unbearable heat) and RPE (22) were recorded every 10 min throughout the 60 186 
min constant load exercise, every 5 min throughout the time trial, and at completion of the time 187 
trial.  Power output was recorded from the ergometer console, with care taken to mask this 188 
from the subject, every 5 min throughout the time trial and in the last few seconds before 189 
completion. Immediately after subjects achieved their work target, a final venous blood sample 190 
was drawn (Post time trial).  Subjects were removed from the chamber to a comfortable 191 
environment and monitored for 15 min to ensure core temperature was declining.  The heart 192 
rate band and thermistors were removed, and subjects fully emptied their bladder once more 193 
for measurement of urine volume and osmolality.  Finally, subjects were reweighed nude, after 194 
towelling off, to assess changes in body mass due to exercising in the warm environment, and 195 
accounting for fluid intake. 196 
 197 
Tyrosine Administration 198 
The total tyrosine administered was zero (PLA), 150 (LOW), 300 (MED) or 400 (HIGH) 199 
mg·kg body mass-1, suspended in 2 × 300 mL drinks.  In LOW 150 mg·kg body mass-1 was 200 
delivered in the first 300 mL drink and in MED and HIGH the tyrosine dose was distributed 201 
equally between the two drinks.  The 150 mg·kg body mass-1 tyrosine was classified as LOW 202 
as this is a common dose used in previous exercise and cognitive function studies but with 203 
mixed outcomes (9).  The MED dose maintained cognitive function in humans exposed to 204 
demanding environmental conditions in previous work (10) and HIGH was employed to 205 
examine the effect of a higher dose than that previously examined in the literature. The total 206 
tyrosine ingested was 11.5 ± 1.0 g in LOW, 23.0 ± 1.9 g in MED and 30.7 ± 2.7 g in HIGH.  207 
All drinks were administered double-blinded and were prepared by a separate drinks supervisor 208 
not directly involved in data collection.  Drinks were served in an opaque sports drink bottle 209 
and were shaken vigorously before administering to subjects.  Prior pilot work confirmed that 210 
the drinks were indistinguishable in taste and texture.   211 
 212 
Blood Handling and Analysis 213 
Six millilitres of blood were drawn into a heparinised vacutainer at each sampling time point.  214 
One millilitre of whole blood was removed from each sample to measure haemoglobin (ABX 215 
Pentra 120, Horiba ABX Diagnostics, Northampton, UK), glucose and lactate (2300 Stat Plus, 216 
Yellow Spring Instrument Co., Ohio, USA), and haematocrit (using microcentrifugation).  217 
Haemoglobin and haematocrit values were used to calculate the percentage change in plasma 218 
volume relative to the baseline sample (23), and values for blood measures were adjusted based 219 
on these changes.  The remaining whole blood in each vacutainer was rapidly centrifuged at 220 
1500 g for 10 min at 4°C to yield plasma. The plasma was distributed equally into two 221 
eppendorfs and immediately stored at -80°C, for later analysis of plasma amino acid 222 
concentrations, as described previously (13).  All blood analyses were carried out in duplicate 223 
except haematocrit measurement which was completed in triplicate.   224 
 225 
Statistical Analysis 226 
All statistical analysis was carried out using a commercial software package (IBM Corp., IBM 227 
SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.). Differences in exercise 228 
time to exhaustion were analysed using one-way, repeated measures ANOVA with a 229 
Bonferroni correction for multiple comparisons.  Data collected at repeated time points in each 230 
trial were analysed using a two-way (trial × time) repeated measures ANOVA.  Where 231 
significant main effects were identified, follow-up paired t-tests with a Bonferroni correction 232 
were used to highlight significant differences in the data.  Calculations of statistical power and 233 
effect sizes (ES) were carried out with G*Power software (version 3.1, Heinrich Heine 234 
University, Dusseldorf, Germany).  All data are presented as mean ± SD, unless stated 235 
otherwise.  Statistical significance for all analyses was accepted at P < 0.05.  Based on the 236 
results of a previous study using a similar exercise protocol in a warm environment (18) we 237 
estimated 90% probability of measuring 3.4 min difference in time trial performance with 9 238 
subjects, with a resultant statistical power of 0.80 and ES of 0.74.   239 
 240 
Results 241 
Time trial performance 242 
The coefficient of variation for performance time between the second familiarisation trial and 243 
PLA was 9.3%.  The results were unaffected by experimental trial order (P = 0.501).  Figure 1 244 
contains the group mean and SD (Figure 1A), individual (Figure 1B) performance times and 245 
power output during the time trial (Figure 1C).  The time trial performance relative to PLA was 246 
unaffected by tyrosine ingestion (P = 0.579).  Power output up to 25 min of the time trial, which 247 
was the last time point which all subjects were still exercising, and at completion was similar 248 
in all trials (P = 0.653).  The statistical power for the time trial performance F-test was 0.68 249 
with an ES of 0.31.  Using this data, a total sample size of 32 is sufficient to identify a 250 
significant difference in the entire F-test at P < 0.05 (G*Power version 3.1).  To achieve 251 
statistical significance in the entire F-test (P < 0.05) with statistical power of 0.80, and with 8 252 
subjects in each group, would require an effect size of 0.35. 253 
 254 
Plasma amino acids 255 
Plasma amino acid concentrations are provided in Table 1.  There were no differences between 256 
trials in the baseline values for all measured amino acids (P > 0.05).  Tyrosine administration 257 
increased the circulating tyrosine concentration relative to PLA (P < 0.001).  Relative to HIGH, 258 
the tyrosine concentration was similar in MED (P = 0.99) but was lower in LOW (P = 0.036).  259 
The plasma concentration ratio of tyrosine: ∑(tryptophan, leucine, isoleucine, valine, 260 
phenylalanine, methionine) (Figure 2) was similar between trials at baseline (P = 0.657).  The 261 
ratio increased with tyrosine ingestion (trial × time interaction, P < 0.001), but was unchanged 262 
in PLA.  The peak increase relative to baseline was similar (P > 0.05) in MED (7.7-fold) and 263 
HIGH (8.2-fold), which was greater than the peak increase in LOW (5.3-fold; P < 0.05).  264 
 265 
Blood glucose and blood lactate 266 
There were no differences between trials in the blood glucose concentration (P = 0.639).  The 267 
baseline blood glucose concentration was 4.5 ± 0.3 mmol·L-1 in PLA, 4.4 ± 0.3 mmol·L-1 in 268 
LOW, 4.5 ± 0.2 mmol·L-1 in MED and 4.5 ± 0.3 mmol·L-1 in HIGH. There was a decline in 269 
blood glucose at pre-exercise (P = 0.003) and post time trial (P = 0.004) compared to baseline, 270 
with no difference at post 60 min relative to baseline (P = 0.249).  The blood glucose 271 
concentration post time trial was 4.0 ± 0.3 mmol·L-1 in PLA, 4.0 ± 0.4 mmol·L-1 in LOW, 3.9 272 
± 0.1 mmol·L-1 in MED and 3.8 ± 0.6 mmol·L-1 in HIGH. Blood lactate was unaffected by trial 273 
condition (P = 0.865) but increased in response to exercise and was higher at post 60 min (P = 274 
0.030) and post time trial (P = 0.004) than at baseline.  The peak blood lactate value, recorded 275 
at the end of the time trial, was 3.0 ± 1.1 mmol·L-1 in PLA, 2.7 ± 1.6 mmol·L-1 in LOW, 3.0 ± 276 
1.0 mmol·L-1 in MED and 2.9 ± 1.3 mmol·L-1 in HIGH. 277 
 278 
Core and skin temperatures 279 
Core temperature increased relative to pre-exercise after 10 min of exercise, throughout the 60 280 
min constant load exercise (P < 0.05) and the time trial (P < 0.001), but no differences were 281 
apparent between trials (P > 0.05; Figure 3).  Due to technical issues with the skin temperature 282 
thermistors, full data sets for five subjects only, were included in the analysis of mean weighted 283 
skin temperature.  Skin temperature increased during the constant load exercise (P = 0.003) 284 
and to a similar extent in each trial (P = 0.347).  Skin temperature remained elevated during 285 
the time trial, relative to the pre-exercise period, but no differences were apparent between 286 
trials (P = 0.704). 287 
 288 
Heart rate 289 
There was a marked increase in heart rate in response to the constant load exercise (P < 0.001) 290 
and the increase was similar between trials (P = 0.718) (Figure 4).  Heart rate continued to 291 
increase during the time trial (P < 0.001) with no differences apparent between trials (P = 292 
0.477).   293 
  294 
RPE and thermal sensation  295 
There were no differences between trials in RPE during 60 min constant load exercise (P = 296 
0.942) or the time trial (P = 0.538) (Table 2).  Expressed RPE increased after 20 min of 297 
exercise, relative to the 10 min value, and remained elevated throughout 60 min of exercise (P 298 
< 0.01).  Perceived exertion was higher at 20 min into the time trial, relative to the 5 min value, 299 
and remained elevated until the end of the time trial (P < 0.05 for all comparisons).  There were 300 
no differences between trials in thermal sensation during 60 min of constant load exercise (P 301 
= 0.824) or the time trial (P = 0.426) (Table 2).  Thermal sensation increased after 5 min of 302 
exercise and remained elevated until the end of 60 min cycling (P < 0.01 for all comparisons).  303 
Thermal sensation continued to rise during the time trial, relative to the value at the start of the 304 
time trial (P < 0.01 for all comparisons), peaking at a subjective rating between “Very hot, 305 
uncomfortable” and “Extremely hot, close to limit”.   306 
 307 
Urine measures and body mass changes 308 
The pre-exercise urine osmolality was 327 ± 225 mosmol·kg-1 in PLA, 405 ± 284 mosmol·kg-309 
1 in LOW, 423 ± 145 mosmol·kg-1 in MED and 471 ± 205 mosmol·kg-1 in HIGH.  Urine 310 
osmolality did not change with time (P = 0.627) and no differences were apparent between 311 
trials (P = 0.645).  Similarly, no differences were apparent between trials in urine volume (P = 312 
0.99).  There was an increase in urine volume (P = 0.026) from pre-exercise (329 ± 324 mL in 313 
PLA, 129 ± 107 in LOW, 212 ± 162 mL in MED and 156 ± 226 mL in HIGH) to post-time 314 
trial (670 ± 389 mL in PLA, 605 ± 474 in LOW, 512 ± 423 mL in MED and 597 ± 439 mL in 315 
HIGH).  The total volume of fluid consumed ad-libitum during the time trial was similar 316 
between trials (P = 0.654; 221 ± 210 mL in PLA; 242 ± 154 mL in LOW; 216 ± 174 mL in 317 
MED and 301 ± 238 mL in HIGH).    There was a reduction in body mass by the end of the 318 
time trial, relative to the pre-exercise value (P = 0.001), which was similar in all trials (P = 319 
0.936), and represented 1.1 ± 0.7 %, 1.4 ± 0.7 %, 1.1 ± 0.7 % and 1.0 ± 0.7 % of the pre-320 
exercise body mass in PLA, LOW, MED and HIGH, respectively.   321 
 322 
Plasma volume  323 
Plasma volume declined, relative to baseline, at pre-exercise (P = 0.018), post 60 min (P = 324 
0.010) and post time trial (P = 0.001) with no difference between trials (P = 0.404).  By the 325 
end of the time trial, the decline in plasma volume relative to baseline was 9.4 ± 5.5 % in PLA, 326 
7.5 ± 3.7 % in LOW, 9.8 ± 2.9 % in MED and 9.3 ± 5.4 % in HIGH.   327 
 328 
Discussion 329 
The results from the study demonstrate no influence on simulated time trial performance in 330 
recreationally trained males exposed to a warm environment despite large increases in the 331 
circulating availability of tyrosine.  The amino acid data suggest that 300 mg·kg-1 tyrosine 332 
maximises the circulating ratio of tyrosine to amino acids competing for brain influx, in young 333 
recreationally trained males, with no additional influence seen with 400 mg·kg-1.  This has 334 
important implications for future work examining tyrosine, given that the acute administration 335 
timescale used in our study is common to research in this area.  The high dose used in the study 336 
is considerably higher than that used in previous studies examining tyrosine administration (10-337 
16, 24, 25) and was well tolerated by all subjects.  This dose was justified given the mixed 338 
outcomes from previous studies on exercise tolerance (12-16, 25) and cognitive functions (9, 339 
25) using lower doses.    340 
 341 
Previous studies in humans typically administering 150 mg·kg body mass-1 tyrosine have 342 
generally failed to show an effect of tyrosine on exercise in temperate (11, 12) or high ambient 343 
temperatures (14, 15) with only one exception (13).  In the Tumilty et al. study (13), exercise 344 
was maintained for 15% longer in 30 °C (60% RH) compared to a placebo.  However, a 345 
separate study using a similar exercise and tyrosine dose protocol could not confirm this finding 346 
(15).  Additionally, exercise performance was not enhanced with 150 mg·kg-1 tyrosine in a 347 
separate study employing the same exercise protocol as the present study (14).  The rationale 348 
for the efficacy of tyrosine to counter exercise impairment is dependent upon stress-induced 349 
depletion of CNS tyrosine availability due to the exercise and environmental demands.  The 350 
core and skin temperatures, heart rate and subjective responses to the exercise protocol and 351 
ambient conditions attest to the demanding nature of the exercise protocol used in the present 352 
study, and in previous work (13-15).    The extent of hyperthermia induced in the present study, 353 
evidenced by the core and skin temperature data, is moderate but reflects the fitness of the 354 
subjects, and the results are similar to other studies in moderately fit subjects at the point of 355 
exhaustion in warm conditions (26).  It is likely that CNS dysfunction would be apparent at the 356 
core temperatures reached in the present study.  Previous work has reported a progressive 357 
decline in motor activation areas in the brain with increasing core temperature, and a reduction 358 
in maximal voluntary contraction force at 38.5°C (27).  These signals most probably integrate 359 
with feedback from working muscles and cardiovascular changes as core temperature 360 
progressively increases, determining exercise fatigue during prolonged exercise in warm 361 
conditions (1).  The progressively increasing RPE and thermal sensation data in the present 362 
study provide some support for this.  Collectively, the present results seem to suggest that 363 
prolonged exercise, with or without exposure to warm ambient temperatures, is insufficiently 364 
stressful to lower CNS neuronal tyrosine availability to the extent that catecholamine function 365 
is markedly impaired.  This is unexpected, considering the specific demands placed on the CNS 366 
when exercise is performed in the heat compared to cooler conditions (1), and the role of brain 367 
catecholamine function to exercise tolerance in the heat (28).   368 
 369 
The present results do not allow us to definitively confirm whether the doses used in the study 370 
are optimal to influence exercise tolerance.  Additionally, given that the subjects were 371 
recreationally trained, a more variable day-to-day cycling performance might be expected 372 
compared to experienced, trained cyclists (29).  The two familiarisation sessions undertaken 373 
prior to the experimental trials in the present study, in subjects involved in regular team sport 374 
training, would be sufficient to ensure reproducibility of the simulated time trial performance 375 
(29).  Several lines of enquiry have reported favourable effects of acute tyrosine 376 
supplementation on various cognitive and psychomotor functions while under stress, using 377 
doses from 150 up to 300 mg·kg body mass-1 (9, 10), providing a rationale for the doses used 378 
in the present study.  Many of these studies have involved military populations involved in 379 
very stressful and prolonged, demanding environments such as sleep deprivation, cold weather 380 
and hypoxia exposure (10, 24).  Prolonged exposure to these environments presumably requires 381 
greater involvement of higher cognitive resources, such as cognitive control and attentional 382 
processes, than prolonged exercise in a warm environment. Under these conditions, it might 383 
therefore, be expected that brain tyrosine becomes depleted to a greater extent than prolonged 384 
exercise in the heat, impairing catecholamine function and dependant processes such as 385 
arousal, motivation and cognitive and psychomotor function.  This might account for the 386 
greater susceptibility of cognitive function to stress-induced impairment and the reported 387 
benefits of tyrosine administration in these studies.  388 
 389 
A primary influence on brain influx of tyrosine is the circulating concentration ratio of tyrosine 390 
to large neutral amino acids which share a L-transport carrier across the blood-brain barrier.  391 
This is the first study to report the effects of several tyrosine doses on this ratio in humans.  392 
Previous reports have examined the effect of ingesting mixed meals containing carbohydrate 393 
and protein on the circulating ratio of tyrosine: competing amino acids (30), or administered 394 
tyrosine in the presence of a mixed meal (25).  This is a crucial consideration since the 395 
additional presence of ingested protein and carbohydrate would influence the circulating 396 
tyrosine ratio independently of tyrosine administration, and directly affect brain uptake and 397 
tissue tyrosine levels (17).  Additionally, one study examined the effect of two separate tyrosine 398 
doses on the circulating tyrosine concentration (150 and 300 mg·kg body mass-1) but did not 399 
report the change in the blood ratio of tyrosine to competing amino acids (25).  The present 400 
data suggest that an acute dose of 300 mg·kg body mass-1 represents an upper limit, on balance, 401 
between the dose administered and the achievable increase in the circulating tyrosine ratio in 402 
recreationally trained male subjects, at least in the time frame adopted in this study.  This is 403 
likely due to a reduced rate of gastric emptying and/ or reduced intestinal transport of the amino 404 
acid into the bloodstream in the presence of the highest ingested tyrosine dose.  Plasma amino 405 
acid concentrations were measured for approximately 2.5 hours after drink administration.  If 406 
the measurement period was extended, this may have appreciably influenced the circulating 407 
tyrosine ratio, highlighting differences between the medium and high dose trials, but we feel 408 
this is unlikely.  We have measured the effect of tyrosine administration on the circulating ratio 409 
of tyrosine: competing amino acids in several studies (published and unpublished 410 
observations), over a time frame of 2.5 to 3 h post-administration.  Typically, an initial peak in 411 
the ratio of tyrosine: competing amino acids is evident 1 to 2 h post-ingestion, and then a 412 
maintenance of this peak, or a modest decline from peak.  Therefore, we feel it is unlikely that 413 
in the present study, the ratio would have appreciably increased from 3 h post-ingestion, to the 414 
extent that differences between the 300 and 400 mg·kg body mass-1 doses would be apparent.   415 
 416 
A limitation of this study, and previous tyrosine studies examining exercise in humans, is a 417 
lack of direct confirmation of brain uptake of the supplemented tyrosine. The ratio of 418 
circulating tyrosine to competing amino acids does correlate well with brain tissue levels in the 419 
rat (31).  In healthy humans, the brain uptake of tyrosine, measured in vivo using positron 420 
emission tomography and intravenous 11C-labelled tyrosine, was reduced following oral 421 
administration of 175 mg·kg body mass-1 (32).  This suggests that the L-carrier amino acid 422 
transporter operates near saturation in fasted and resting humans.  Some caution is warranted 423 
in generalising these findings as this may not be representative of brain tyrosine transport 424 
kinetics in humans exposed to environmental stress or exercise.  Nonetheless, this might 425 
account in part for the general lack of influence of tyrosine on exercise tolerance.  The accepted 426 
thinking for some time is that catecholamine synthesis is tightly controlled within the CNS via 427 
receptor-mediated end-product inhibition of the rate-limiting enzyme tyrosine hydroxylase, 428 
with around 75%  saturation of the enzyme under basal conditions (6).  This would limit the 429 
extent that CNS catecholamine function was influenced, or even inhibit further catecholamine 430 
synthesis  (33),  in the presence of elevated  brain tyrosine availability, unless the stress 431 
exposure was excessively demanding and prolonged.  This situation is quite different from the 432 
central synthesis of serotonin which tends to readily increase in line with brain content of its 433 
amino acid precursor tryptophan (34).  Recent research using microdialysis in the rat seems to 434 
counter the extent to which tyrosine hydroxylase is saturated in vivo.  Perfusing the striatum 435 
and prefrontal cortex with L-tyrosine under awake, resting conditions markedly increased 436 
DOPA in dopamine nerve terminals, with a dose dependant increase in striatum (35).  437 
Bypassing the rate-limiting step in catecholamine in humans, for example with Levodopa (L-438 
DOPA) administration, exerts a more pronounced influence on brain catecholamine activity in 439 
humans (36).  Administering potent stimulators of the catecholaminergic system such as 440 
amphetamine  (37) or a dopamine/ noradrenaline reuptake inhibitor (18) more robustly 441 
enhances exercise performance.  Interestingly, selectively inhibiting CNS noradrenaline 442 
reuptake impairs prolonged exercise in a warm environment (38) suggesting an important role 443 
for CNS dopamine function during prolonged exercise in the heat.   444 
 445 
Given that tyrosine is a general catecholamine precursor, some influence on CNS noradrenaline 446 
function cannot be ruled out in the present study.  Improved blood pressure maintenance and 447 
increased auditory event related potential amplitude have been reported in humans during 448 
lower body negative pressure exposure, following acute 150 mg·kg body mass-1 tyrosine 449 
supplementation (39).  These effects are consistent with an influence of tyrosine on central 450 
noradrenergic function.  Recent work reported that 150 mg·kg body mass-1 oral tyrosine 451 
administration improved skin vasoconstrictive responses to cold exposure in older people, 452 
suggesting augmented peripheral noradrenergic effector responses (40).  Older people can 453 
exhibit lowered endogenous tyrosine availability and blunted peripheral noradrenergic 454 
responses (40).  This may be unrepresentative of young, healthy males exercising in warm 455 
conditions.  The absence of an influence of tyrosine administration on skin temperature 456 
responses in the present study, and others involving young, healthy subjects exercising in warm 457 
conditions (13-15), lends support for this. 458 
 459 
Conclusion 460 
Increasing the circulating ratio of tyrosine to amino acids competing for brain uptake with a 461 
low, medium or high tyrosine dose had no influence on prolonged exercise performance in a 462 
warm environment, in male recreationally trained subjects.  The results do not preclude an 463 
important role of CNS catecholamines during prolonged exercise in a warm environment, but 464 
the weight of evidence suggests this is not appreciably influenced by increasing peripheral 465 
precursor availability, in the subject group examined.  This probably suggests that the exercise 466 
and ambient conditions were insufficiently stressful to lower CNS tyrosine availability in 467 
recreationally trained male, and further catecholamine synthesis is feedback-inhibited, or that 468 
the additional circulating tyrosine is not fully available to the CNS.  The results also report, for 469 
the first time, data in humans on the response of several tyrosine doses.  The results suggest 470 
that 300 mg·kg body mass-1 tyrosine is optimal to maximise the circulating ratio of tyrosine: 471 
amino acid competing for brain uptake, in recreationally trained males.  This provides 472 
important insight for future studies examining the acute effect of tyrosine administration.   473 
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 587 
FIGURE 1- Effect of placebo or tyrosine ingestion on the group mean ± SD (A) and individual 588 
(B) performance times and power output (C) during a simulated cycling time trial in the heat. 589 
PLA 0, LOW 150 mg·kg-1, MED 300 mg·kg-1, HIGH 400 mg·kg-1tyrosine trial. 590 
 591 
FIGURE 2- Effect of placebo or tyrosine ingestion on the plasma concentration ratio of tyrosine 592 
to large neutral amino acids competing for brain influx. *P < 0.05 denotes significant difference 593 
compared to the 150 mg·kg body mass-1 tyrosine trial.   ***P < 0.001 denotes significant 594 
difference compared to the placebo trial. Values are mean ± SD.  ∑LNAA, ∑(plasma 595 
concentration of free-tryptophan, leucine, isoleucine, valine, phenylalanine, methionine). PLA 596 
0, LOW 150 mg·kg-1, MED 300 mg·kg-1, HIGH 400 mg·kg-1tyrosine trial. 597 
 598 
FIGURE 3-Core (A) and mean weighted skin (B) temperature responses to exercise in the heat 599 
with placebo or tyrosine ingestion. 
c
P < 0.001 denotes significant difference to remaining time 600 
points in all trials.  Values are mean ± SD.  PLA 0, LOW 150 mg·kg-1, MED 300 mg·kg-1, 601 
HIGH 400 mg·kg-1 tyrosine trial. 602 
 603 
FIGURE 4- Heart rate responses to exercise in the heat with placebo or tyrosine ingestion. 
c
P 604 
< 0.001 denotes significant difference to remaining time points in all trials.  Values are mean 605 
± SD.  PLA 0, LOW 150 mg·kg-1, MED 300 mg·kg-1, HIGH 400 mg·kg-1 tyrosine trial. 606 
TABLE 1-Plasma amino acid responses to exercise with placebo or tyrosine ingestion. 
      Baseline Pre-exercise Post 60 min Post time trial 
     
Tyrosine (µmol·L-1)     
   PLA 116 ± 17 106 ± 18 112 ± 21 109 ± 16 
   LOW 113 ± 25 428 ± 154***, a 481 ± 177***, a 404 ± 143***, a 
   MED 112 ± 17 436 ± 124***, a 635 ± 190***, *, a 618 ± 129***, *, a 
   HIGH 115 ± 27 448 ± 114***, a 635 ± 162***, *, a 668 ± 141***, *, a 
Valine (µmol·L-1)     
   PLA 395 ± 74 356 ± 67 320 ± 65 b 299 ± 77 b 
   LOW 345 ± 78 377 ± 85 317 ± 59 b 250 ± 66 b 
   MED 352 ± 44 323 ± 44 296 ± 47 b 271 ± 44 b 
   HIGH 366 ± 67 340 ± 60 299 ± 70 b 281 ± 51 b 
Leucine (µmol·L-1)     
   PLA 211 ± 47 183 ± 37 149 ± 41 a 135 ± 30 a 
   LOW 175 ± 52 185 ± 62 143 ± 37 a 114 ± 36 a 
   MED 189 ± 35 162 ± 34 143 ± 31 a 115 ± 20 a 
   HIGH 207 ± 43 171 ± 32 146 ± 36 a 120 ± 18 a 
Isoleucine (µmol·L-1)     
   PLA 93 ± 20 81 ± 16 67 ± 14 a 64 ± 14 a 
   LOW 81 ± 27 83 ± 25 64 ± 14 a 53 ± 14 a 
   MED 84 ± 19 73 ± 17 63 ± 12 a 55 ± 10 a 
   HIGH 84 ± 23 71 ± 17 61 ± 17 a 54 ± 9 a 
Methionine (µmol·L-1)     
   PLA 25 ± 2 24 ± 3 25 ± 3 26 ± 3 
   LOW 26 ± 5 27 ± 4 25 ± 3 24 ± 3 
   MED 26 ± 4 25 ± 4 25 ± 4 24 ± 4 
   HIGH 26 ± 5 25 ± 4 24 ± 5 24 ± 5 
Phenylalanine (µmol·L-1)     
   PLA 74 ± 8 73 ± 9 80 ± 8 80 ± 6 
   LOW 69 ± 15 76 ± 11 78 ± 15 75 ± 19 
   MED 72 ± 11 75 ± 17 76 ± 12 77 ± 16 
   HIGH 76 ± 7 75 ± 5 79 ± 10 81 ± 15 
Tryptophan (µmol·L-1)     
   PLA 122 ± 7 118 ± 14 108 ± 14 87 ± 15 b 
   LOW 116 ± 23 126 ± 19 114 ± 23 93 ± 23 b 
Table 1
 
PLA 0, LOW 150 mg·kg-1, MED 300 mg·kg-1, HIGH 400 mg·kg-1 tyrosine trial.  *P < 0.05 
denotes significant difference to the LOW trial.  ***P < 0.001 denotes significant difference 
compared to the PLA trial.  
a
P < 0.05 and 
b
P < 0.01 denotes significant difference compared 
to the baseline value in the same trial.  Values are mean ± SD. 
 
 
   MED 116 ± 16 121 ± 14 106 ± 11 91 ± 10 b 
   HIGH 127 ± 22 126 ± 20 110 ± 25 96 ± 23 b 
TABLE 2-Subjective responses to exercise in the heat with placebo or tyrosine ingestion. 
 
PLA 0, LOW 150 mg·kg-1, MED 300 mg·kg-1, HIGH 400 mg·kg-1 tyrosine trial.  
a
P < 0.05 and 
b
P < 0.01 denotes significant difference compared to the first value recorded in the same trial 
and exercise period.  Values are mean ± SD. 
 60 min constant load cycling 
         0 10 20 30 40 50 60 
        Rating of perceived exertion (RPE; 6 – 20) 
   PLA ̶ 13 ± 1 13 ± 2 b 14 ± 2 b 14 ± 2 b 14 ± 2 b 14 ± 2 b 
   LOW ̶ 12 ± 2 13 ± 2 b 14 ± 2 b 14 ± 2 b 14 ± 2 b 15 ± 2 b 
   MED ̶ 12 ± 1 13 ± 1 b 13 ± 2 b 14 ± 2 b 14 ± 2 b 15 ± 2 b 
   HIGH ̶ 13 ± 1 13 ± 1 b 13 ± 1 b 14 ± 1 b 15 ± 2 b 15 ± 1 b 
Thermal sensation (-10 unbearable cold; 0 neutral; 10 unbearable heat) 
   PLA 2 ± 1 4 ± 1 b 4 ± 2 b 4 ± 2 b 5 ± 2 b 5 ± 2 b 5 ± 2 b 
   LOW 2 ± 1  4 ± 1 b 4 ± 2 b 5 ± 1 b 5 ± 2 b 5 ± 2 b 6 ± 2 b 
   MED 2 ± 1 4 ± 1 b 4 ± 1 b 5 ± 1 b 5 ± 2 b 5 ± 2 b 6 ± 2 b 
   HIGH 2 ± 1 4 ± 1 b 4 ± 1 b 5 ± 2 b 5 ± 2 b 5 ± 2 b 5 ± 2 b 
        
        Simulated time trial 
         0 5 10 15 20 25 END 
 Rating of perceived exertion (RPE; 6 – 20) 
   PLA ̶ 15 ± 2 15 ± 2 15 ± 2 16 ± 2 a 16 ± 3 a  18 ± 2 a 
   LOW ̶ 15 ± 2 15 ± 2  16 ± 1 16 ± 1 a  16 ± 2 a  18 ± 2 a 
   MED ̶ 14 ± 2 15 ± 2 15 ± 2 16 ± 2 a   16 ± 2 a   18 ± 2 a 
   HIGH ̶ 14 ± 2 15 ± 2 15 ± 2 16 ± 2 a  16 ± 2 a 18 ± 2 a 
Thermal sensation (-10 unbearable cold; 0 neutral; 10 unbearable heat) 
   PLA 4 ± 2 5 ± 2 b 6 ± 2 b 6 ± 3 b 6 ± 2 b 6 ± 2 b 7 ± 2 b 
   LOW 4 ± 2 5 ± 2 b 6 ± 2 b 6 ± 2 b 6 ± 2 b 7 ± 2 b 7 ± 2 b 
   MED 4 ± 1 5 ± 2 b 6 ± 2 b 6 ± 2 b 6 ± 2 b 6 ± 2 b 7 ± 2 b 
   HIGH 4 ± 1 5 ± 2 b 5 ± 2 b 6 ± 2 b 6 ± 2 b 6 ± 2 b 7 ± 2 b 
Table 2
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